top of page



Sotirios Stergiopoulos, MD, MBEE, FACP

President & CEO, Founder

​Harvard Medical School, Bayer, Novartis, Celgene, CMO of Ipsen

  • Chief Medical Officer, SVP and Head of Global Medical Affairs at Ipsen

  • Vice President and Head of Global Medical Affairs Oncology for Baxalta Inc and Shire & roles in medical affairs and clinical development at Bayer Pharmaceuticals, Novartis Pharmaceuticals and Celgene Corporation 

  • Trained in Internal Medicine and Cancer Genetics from NIH, Albert Einstein College of Medicine and Harvard Medical School

  • Masters of Biotechnology Enerprise and Entrepreneurship from Johns Hopkins University


Edward Painter, MBA

Chairman & CIO, Founder

Research and Biotech focused capital markets with Goldman Sachs, Credit Suisse & UBS​

  • MBA from University of Illinois at Urbana-Champaign

  • Former VP at UBS, Oppenheimer & Co., Credit Suisse, and Kidder Peabody

  • Former analyst at Goldman Sachs and Salomon Brothers

  • 30 years of experience in finance

  • Has worked extensively with biotech companies in financing and investment decisions

Screen Shot 2019-05-11 at 3.54.41 PM.png

Sridhar Vempati

Chief Strategy Officer & Executive VP of R&D, Founder

Harvard University Postdoc Leukemia Research, BD Ironwood and Rafael Pharma​

  • PhD in Human Biology from Ludwig-Maximilians University

  • MBA from Boston University

  • Postdoctoral research at Harvard University in leukemia and the target of AO-001

  • Authored several articles in oncology in leading publications

  • Biotechnology industry analyst experience at Jeffries LLC 


Chaemin Lim, PhD

Chief Scientific Officer

Medicinal and Computational Chemist. Seoul National University, University of Pittsburgh, UPCDC ​

  • PhD in Synthetic and Medicinal Chemistry from the Seoul National University

  • Postdoctoral research in Chemistry from the University of Pittsburgh

  • Extensive research experience in synthetic organic chemistry and drug discovery covering multiple therapeutic areas

  • Co-authored 20 SCI papers and 9 patent applications as a co-inventor

  • Has contributed to drug discovery and development projects ranging from early development stages through to preclinical trials particularly using in silico drug design tools

emmauel headshot.jpg

Emmanuel Cruz, M.Eng, B.S.

Head of Technology Innovation

Machine Learning and Computational Chemist 

  • Master in Computer Science, Cornell Tech

  • Chemist, Univ. South Florida

  • Bryd Alzheimers Institute, Center of Disease and Drug Innovation Medicinal Chemist

  • Development of Novel Therapeutics using Cannabinoid analogs for Alzheimer's and Other Neurodegenerative Diseases. 

bottom of page